Various clinical data demonstrate the crucial role CGRP plays in migraine pathology, and there are several different methods of blocking CGRP activity to treat migraine attacks.
1. Gepants – CGRP receptor antagonists, which bind to the CGRP receptor and prevent signalling.
2. Anti-CGRP antibodies, which prevent CGRP interacting with its receptor.
3. Anti-CGRP receptor antibodies, which bind to the CGRP receptor and prevent signalling.
Read more about anti-CGRP therapies and their mechanism of action
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
An analysis of the Global Burden of Disease (GBD) study showed that migraine and headache disorders were leading causes of years lived with disability, and that for individuals aged 15–49 years, migraine is the leading cause of disability for women.
Migraine attacks can be broken down into four phases: prodrome, aura, headache, and postdrome, as shown on the image. The exact timing of each phase is highly variable; the headache phase of a migraine can range from 4–72 hours in adults, and 2–48 hours in children.